Evotec SE (EVOTF)
| Market Cap | 879.46M -30.0% |
| Revenue (ttm) | 887.40M -2.7% |
| Net Income | -186.53M |
| EPS | -1.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 700 |
| Average Volume | 1,393 |
| Open | 5.24 |
| Previous Close | 4.73 |
| Day's Range | 5.24 - 5.24 |
| 52-Week Range | 4.73 - 8.58 |
| Beta | 1.12 |
| RSI | 33.59 |
| Earnings Date | Apr 8, 2026 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease... [Read more]
Financial Performance
In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.
Financial numbers in EUR Financial StatementsNews
EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Evotec SE / Preliminary announcement on the disclosure of financial statements Evotec SE: Preliminary announcement of the publication of quarterly repor...
EQS-AFR: Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Evotec SE / Preliminary announcement on the disclosure of financial statements Evotec SE: Preliminary announcement of the publication of financial repor...
Evotec SE: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yieldsManufacturing proce...
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process...
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment i...
Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE (NASDAQ: EVO). The investigation focuses on Evotec executive of...
Evotec Restructuring Aims To Improve Profitability After Transition Year
Evotec SE (NASDAQ: EVO) stock is trading lower on Tuesday.
Evotec Restructuring Aims To Improve Profitability After Transition Year
Evotec SE (NASDAQ: EVO) stock is trading lower on Tuesday. The drug discovery firm announced a new strategic transformation initiative called "Horizon," aimed at reshaping its operating model, improv...
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limi...
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / Janua...
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBU...
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to ...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statemen...
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October ...
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Pre...
Evotec SE to announce first half-year results 2025 on 13 August 2025
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim r...
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...
Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license reven...
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its ...